Professor, Medicine, Indiana University School of Medicine
Oncology
Dr. Rudolph M. Navari, MD
|
|
Give Review
Doctor Rudolph M. Navari, MD works in the field of Oncology. He studied medicine at University of Alabama Medical Center. University of Alabama Medical Center is ranked 37/17 in Research/PrimaryCare. Dr. Rudolph M. Navari is a published MD. He has 86 papers published. The most current publication "Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group." He accepts Medicare.
Publications
- Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracyclin...
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in ...
- Clinical trial data in chemotherapy-induced nausea and vomiting.
- New data in emerging treatment options for chemotherapy-induced nausea and vomiting in clinical practice: general discussion.
- Olanzapine for the prevention and treatment of Chronic nausea and chemotherapy-induced nausea and vomiting.
- Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site.
- The current status of the use of palonosetron.
- Management of Chemotherapy-Induced Nausea and Vomiting : Focus on Newer Agents and New Uses for Older Agents.
- The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemothe...
- Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography.
- Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
- An accompanying genetic severe deficiency of Tissue factor protects mice with a protein C deficiency from lethal endotoxemia.
- Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
- New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations.
- Symptomatic treatment of infections in patients with advanced Cancer receiving hospice care.
- A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in Cancer patients: a Hoosier Oncology Group study.
- Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
- Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.
- Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
- Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
- Antimicrobial use in patients with advanced Cancer receiving hospice care.
- Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
- International study in premedical education.
- Preferences of patients with advanced Cancer for hospice care.
- A prisoner with Chronic myeloid leukemia.
- Use of placebos in delayed-emesis studies.
- Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
- Single-dose Oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
- Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed...
- Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic Cancer chemo...
- Prevention of acute emesis in Cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
- The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
- Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
- Fadrozole hydrochloride in postmenopausal patients with metastatic Breast carcinoma.
- Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-indu...
- Protein turnover in advanced lung Cancer patients.
- Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cispl...
- Treatment of Cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
- Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
- Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
- Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
- Functional, morphological, and metabolic abnormalities of the cerebral microcirculation after concussive brain injury in cats.
- Renal adenoCarcinoma associated with multiple simple cysts.
- Mechanism of cerebral arteriolar abnormalities after acute hypertension.
- The peripheral blood smear in heat stroke. An aid to diagnosis.
- Hypothermia.
- Prophylaxis of infection in patients with aplastic Anemia receiving allogeneic marrow transplants.
- Bone marrow necrosis in acute Leukemia.
- Mycobacterial infections in marrow transplant patients.
- Pneumatosis cystoides intestinalis following allogeneic marrow transplantation.
- Laboratory experiments using nicotine.
- Effect of plasma proteins on oxygen diffusion in the pulmonary capillaries.
- Treatment of marrow graft recipients with thymopentin.
- Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
- Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
- Glucose metabolism in advanced lung Cancer patients.
- Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of...
- Mass transfer properties of gases in fluorocarbons.
- In vitro depression of Tissue oxygen uptake by liquid fluorocarbon prepared as artificial blood.
- Inhibition of rat bronchiolar oxygen consumption by plasma proteins.
- Role of Tissue hypoxia in local regulation of cerebral microcirculation.
- Responses of cerebral arteries and arterioles to acute hypotension and hypertension.
- Oxygen consumption of pial arteries.
- Comparison of the open skull and cranial window preparations in the study of the cerebral microcirculation.
- The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.
- Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
- A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
- Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
- Emerging drugs for chemotherapy-induced emesis.
- Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting.
- Cathepsin E is a specific marker of dysplasia in APC mouse intestine.
- Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
- Treatment of depressive symptoms in patients with early stage breast Cancer undergoing adjuvant therapy.
- Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
- A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
- Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with Cancer.
- Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
- Treatment of Cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.
- Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
- Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
- Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
- Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.
- Highlights from: The 40th Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA.
- Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic Breast carcinoma.
Schools
Virginia Commonwealth University School Of Medicine
University Ala
University Washington
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Alabama Medical Center -
Virginia Commonwealth University School of Medicine
Drug Facts
| NPI NUMBER | 1891778023 | |
| NPPES Provider LastName | NAVARI | |
| NPPES Provider FirstName | RUDOLPH | |
| NPPES Provider ZIPCode | 466172808 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 498.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 5.82 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891778023 |
| Last Name Of The Provider | NAVARI |
| First Name Of The Provider | RUDOLPH |
| View All |
Similar Doctors
|
|
Dr. Rafat H. Ansari, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William S. Kamanda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robin T. Zon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lowell D. Smith, MD |